Calyxt (CLXT) Stock Price

Calyxt Price

Delisted

Revenue at Calyxt has contracted by 25.8% per year over the past 7 years to 157,000.00 USD. For Calyxt, the net margin of -6,243.9% is up versus -11,820.8% a few years ago. Of 8 analysts, 0 rate the stock a buy — an overall Hold consensus.

Calyxt stock price

Volume
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Calyxt over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Calyxt stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Calyxt's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Calyxt Stock Price History
DateCalyxt Price
Access this data via the Eulerpool API

Calyxt Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
23.85 M USD
-43.96 M USD
-46.40 M USD
Jan 1, 2021
25.99 M USD
-29.33 M USD
-29.09 M USD
Jan 1, 2022
157,000.00 USD
-22.37 M USD
-9.80 M USD
Jan 1, 2023 (e)
2.50 M USD
-12.14 M USD
-172.82 M USD
Jan 1, 2024 (e)
0.00 USD
-12.75 M USD
-133.32 M USD
Jan 1, 2025 (e)
0.00 USD
-13.36 M USD
-15.61 M USD
Jan 1, 2026 (e)
74.54 M USD
-760,920.00 USD
-503,637.25 USD
Jan 1, 2027 (e)
141.29 M USD
29.89 M USD
14.61 M USD

Calyxt Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 6:16 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023e2024e2025e2026e2027e2028e
1.007.0023.0025.002.0074.00141.00232.00
228.578.7090.5464.54
-200.00-14.29-47.83-8.00-8.00-8.00-8.00-8.00
-2.00-2.00-2.00-2.00-1.00-11.00-2.00-2.00-0.16-2.00-2.00-5.92-11.28-18.56
-5.00-12.00-25.00-28.00-39.00-43.00-29.00-22.00-12.00-12.00-13.0029.00
-500.00-557.14-186.96-116.00-600.0020.57
-5.00-12.00-25.00-27.00-41.00-46.00-29.00-9.00-172.00-133.00-15.0014.0035.00
140.00108.338.0051.8512.20-36.96-68.971,811.11-22.67-88.72150.00
48.4426.6027.8532.6832.9936.2838.2848.4448.4448.4448.4448.4448.4448.44
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Calyxt generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Calyxt retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Calyxt's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Calyxt has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Calyxt's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Calyxt stock margins

The Calyxt margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Calyxt. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Calyxt.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
100.00 %
-11,913.14 %
-11,820.76 %
Jan 1, 2019
-27.19 %
-543.76 %
-563.35 %
Jan 1, 2020
-47.28 %
-184.30 %
-194.54 %
Jan 1, 2021
-9.89 %
-112.87 %
-111.92 %
Jan 1, 2022
100.00 %
-14,248.41 %
-6,243.95 %
Jan 1, 2023 (e)
100.00 %
-485.52 %
-6,912.67 %
Jan 1, 2024 (e)
100.00 %
- %
- %
Jan 1, 2025 (e)
100.00 %
- %
- %

Calyxt Stock Revenue, EBIT, Earnings per Share

The Calyxt earnings per share therefore indicates how much revenue Calyxt has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.36 USD
-43.02 USD
-42.68 USD
Jan 1, 2019
11.06 USD
-60.13 USD
-62.30 USD
Jan 1, 2020
32.87 USD
-60.58 USD
-63.94 USD
Jan 1, 2021
33.95 USD
-38.32 USD
-37.99 USD
Jan 1, 2022
0.16 USD
-23.09 USD
-10.12 USD
Jan 1, 2023 (e)
2.53 USD
-12.53 USD
-175.00 USD
Jan 1, 2024 (e)
0.00 USD
-13.16 USD
-135.00 USD
Jan 1, 2025 (e)
0.00 USD
-13.79 USD
-15.81 USD

Calyxt business model & stock analysis

Calyxt Inc. is a US company specializing in the development and marketing of genetically modified plants. The company was founded in Minnesota in 2010 with the aim of producing high-quality, healthy, and environmentally friendly products that meet the requirements of modern and sustainable nutrition. History The history of Calyxt Inc. began with the idea of revolutionizing the cultivation of crops. The company was founded by Cellectis SA, which already had experience in the field of molecular biology. Calyxt developed technological processes for rapid genetic manipulation of plants that had the potential to change the entire agricultural industry. Business Model Calyxt follows an "end-to-end" business model, meaning the company offers products and services along the entire value chain. This ranges from the development of new plants through genetic modifications to the distribution and marketing of the end products. Divisions Calyxt specializes in the development of plant varieties optimized through genetic manipulation. The company has various divisions that focus on specific plant species, including: - Soybeans: Calyxt has developed a new variety of soybeans that contains a higher proportion of oleic acid, which improves the durability and quality of the beans. - Wheat: The company has also developed a variety of wheat that is low in gluten. This allows people with celiac disease or other reasons to avoid gluten to consume this variety. - Potatoes: Calyxt has developed a new variety of potatoes that contains less acrylamide than other varieties. Acrylamide is formed during the production of fries and chips and is suspected to cause cancer. Products Calyxt offers various products made from the plants they have developed, including: - Soybean oil: Calyxt soybean oil contains a higher proportion of healthy omega-3 fatty acids compared to conventional soybean oil. - Flour: Calyxt wheat flour is low in gluten and can be consumed by people with celiac disease or other reasons to avoid gluten. - Fries and chips: Calyxt potatoes contain less acrylamide than conventional potatoes, resulting in the formation of fewer harmful substances during the preparation of fries and chips. Conclusion Calyxt Inc. is an American company that develops genetically modified plants and connects them with customers, mainly in the food sector. The company aims to produce healthy, environmentally friendly, and high-quality products that meet the requirements of modern and sustainable nutrition. Various plant species are genetically modified to improve the durability and quality of the products while minimizing health risks. Calyxt Inc. offers various products made from the plants they have developed, with a focus on the production of fries and chips, as well as the distribution of soybean oil and low-gluten wheat flour. Calyxt has the potential to change modern agriculture through its innovative and sustainable products.

Calyxt SWOT Analysis

Strengths

Calyxt Inc possesses several strengths that contribute to its success in the market:

  • Advanced gene-editing technology allows for precise modification of plants
  • Diverse portfolio of genetically modified crops
  • Strong intellectual property rights for their technologies
  • Experienced and knowledgeable team of scientists and researchers
  • Ability to create crops with enhanced nutritional qualities
  • Strong brand reputation and recognition

Weaknesses

Calyxt Inc also faces certain weaknesses that pose challenges to its operations:

  • Relatively high production costs compared to conventional breeding methods
  • Limited market adoption of genetically modified crops
  • Stringent regulations and public resistance towards genetically modified organisms (GMOs)
  • Potential negative impact on biodiversity and ecosystem balance
  • Dependence on partnerships and collaborations for commercialization

Opportunities

Opportunities for Calyxt Inc to grow and expand in the industry include:

  • Increasing market demand for sustainable and healthier food options
  • Rapid advancements in genetic engineering technology
  • Expanding global market for genetically modified crops
  • Potential collaborations with agribusiness giants for wider distribution
  • Exploration of new crop varieties and traits

Threats

Calyxt Inc should be wary of the following threats that could impact its business:

  • Increased regulatory scrutiny and restrictions on genetically modified organisms
  • Competition from other biotech companies in the market
  • Public perception and resistance towards GMOs
  • Shifts in consumer preferences towards organic and non-GMO products
  • Fluctuating economic and market conditions

Calyxt Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Calyxt Employees
Details
Date
Calyxt Employees
Jan 1, 2017
- Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Calyxt Segments

Calyxt Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Product and Service, Other
Other
High Oleic Soybean Grain
High Oleic Soybean Meal
High Oleic Soybean Oil
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Calyxt Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
High oleic soybean meal
High oleic soybean oil
Licensing of Technology
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Calyxt Revenue by Segment (3/3)

  • Max

Reportable Segment
Details
Date
Reportable Segment
Jan 1, 2024
4.26 M USD
Jan 1, 2025
3.64 M USD

Calyxt Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Calyxt historical P/E ratio, EBIT multiple, and P/S ratio

Calyxt annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Calyxt shares outstanding

The number of shares of Calyxt was 968,858 in 2025. This indicates how many shares Calyxt is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
653,558.00 Stocks
Jan 1, 2019
659,762.00 Stocks
Jan 1, 2020
725,660.00 Stocks
Jan 1, 2021
765,546.00 Stocks
Jan 1, 2022
968,858.00 Stocks
Jan 1, 2023 (e)
968,858.00 Stocks
Jan 1, 2024 (e)
968,858.00 Stocks
Jan 1, 2025 (e)
968,858.00 Stocks

Calyxt stock splits

In Calyxt's history, there have been no stock splits.

Current Calyxt forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
400.00 %
Buy
0.00 % (0)
Hold
62.50 % (5)
Sell
37.50 % (3)
12M Price Target
36.98
Last Price
0.00
Currency
USD
12M Return Potential
0 %
LTM Return
0 %

Calyxt Analyst Rating Actions

DateFirmActionRatingReliability
11/4/2022
HC Wainwright & Co.
HC Wainwright & Co.
DowngradeBuyNeutral
3/4/2022
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
11/2/2021
Roth Capital
Roth Capital
MaintainedBuy
12/15/2020
Berenberg
Berenberg
MaintainedBuy
12/10/2020
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy
7/28/2020
Canaccord Genuity
Canaccord Genuity
MaintainedBuy59
5/15/2020
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
5/8/2020
BMO Capital
BMO Capital
DowngradeOutperformPerform
3/6/2020
Wells Fargo
Wells Fargo
DowngradeOverweightEqual Weight56
3/6/2020
Goldman Sachs
Goldman Sachs
DowngradeBuyNeutral

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Calyxt Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/2/2023-0.30USD-4.87 MUSD-2023 Q2
5/3/2023-0.31USD-4.36 MUSD-2023 Q1
3/1/2023-0.11USD-1.17 MUSD-2022 Q4
11/3/2022-0.15USD-274,050.00USD-2022 Q3
8/4/2022-0.14USD-145,479.00USD-2022 Q2
5/5/2022-0.16USD-583,625.00USD-2022 Q1
3/3/2022-0.42USD-2.68 MUSD-2021 Q4
11/4/2021-0.16USD-4.10 MUSD-2021 Q3
8/5/2021-0.19USD-6.23 MUSD-2021 Q2
5/6/2021-0.26USD-4.49 MUSD-2021 Q1

Calyxt shareholder structure

% Name
48.53183%
Cellectis S.A.
Cellectis S.A.
1.47447%
Carr (Michael A)
Carr (Michael A)
1.23819%
Koschak (William)
Koschak (William)
1.23218%
Frey (Travis)
Frey (Travis)
1.22223%
Frimerman (Debra H.)
Frimerman (Debra H.)
1.10510%
Renaissance Technologies LLC
Renaissance Technologies LLC

Calyxt Beneficial Ownership Filings (SEC 13D/G)

Free Float
50.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
64.70%
Cellectis S.A.
Cellectis S.A.
SEC ↗
33.02%
Rory B. Riggs
Rory B. Riggs
SEC ↗
15.00%
FMR LLC
FMR LLC
SEC ↗
15.00%
Mark T. Finn
Mark T. Finn
SEC ↗
14.60%
Jonathan Finn
Jonathan Finn
SEC ↗
12.23%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
9.60%
JPL Investments SA
JPL Investments SA
SEC ↗
9.60%
Jean-Pierre J. Lehmann
Jean-Pierre J. Lehmann
SEC ↗
6.50%
New Ventures I, LLC
New Ventures I, LLC
SEC ↗
5.67%
Fidelity Growth Company Fund
Fidelity Growth Company Fund
SEC ↗

Calyxt Supply Chain

Calyxt Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Cellectis
Supplier·Customer·Biotechnology·FR
0.36
0.92
0.49
0.92
0.97
0.73
2
S&W Seed
Supplier·Customer·Food Products·US
-0.22
0.81
0.89
0.94
0.86
0.56

Frequently asked questions about Calyxt

Calyxt Inc's business model revolves around utilizing gene editing technology to develop healthier and more sustainable products. As a leading agricultural biotechnology company, Calyxt focuses on creating gene-edited crops with improved traits, such as enhanced nutrition, and reduced chemical inputs. By leveraging cutting-edge technologies like TALEN® and CRISPR/Cas9, Calyxt aims to address global challenges in the agriculture and food industry. With a commitment to environmental stewardship and consumer wellness, Calyxt Inc strives to revolutionize agricultural practices and contribute to a more sustainable future.

Calyxt Inc is primarily active in the agricultural industry, specializing in the development and commercialization of high-value crops through gene editing technology. With a focus on producing healthier, sustainable food ingredients, Calyxt Inc operates in sectors such as plant-based proteins, oils, and specialty food ingredients. Through their innovative gene-editing techniques, the company aims to improve crop traits, enhance nutritional value, and reduce environmental impact in the agricultural sector. Calyxt Inc's commitment to revolutionizing the food industry sets them apart as a leading player in developing healthier and more sustainable agricultural solutions.

The main competitors of Calyxt Inc in the market include companies such as Cibus, DuPont Pioneer, and Benson Hill Biosystems.

Calyxt Inc is a company with a rich history and background. Founded in 2010, Calyxt is a leading agricultural biotechnology company that focuses on developing healthier food products. With a mission to deliver high-value traits and healthier foods using cutting-edge gene-editing technologies, Calyxt has revolutionized the industry. Their expertise lies in using TALEN® technology to create gene-edited plants that enhance nutrition, reduce allergenicity, and improve crop quality. By working closely with farmers, food suppliers, and consumers, Calyxt aims to create sustainable and nutritious food solutions for a better future. Calyxt Inc continues to make significant strides in the field of agriculture and biotechnology.

Calyxt Inc, a leading biotechnology company, has achieved several significant milestones. First and foremost, the company successfully developed and commercialized high-value plant products using TALEN® gene-editing technology. This breakthrough technology enables precise modifications in plant genomes, resulting in improved crop traits and enhanced yields. Additionally, Calyxt Inc received regulatory approval for its high oleic soybean product, further demonstrating its commitment to innovation in the agricultural sector. The company continues to drive advancements in plant breeding, offering sustainable solutions to meet growing global food demands. Calyxt Inc's dedication to excellence and cutting-edge research positions it as a key player in the biotechnology industry.

Calyxt Inc is primarily present in the United States.

Calyxt Inc represents values of innovation, sustainability, and ethical practices. The company's corporate philosophy revolves around harnessing the power of cutting-edge gene-editing technology to develop healthier and more sustainable food products. Calyxt is committed to providing consumers with nutritional and environmentally friendly solutions by creating crops with improved characteristics and reduced chemical usage. With a focus on precision breeding techniques, Calyxt aims to revolutionize the agricultural industry and address global challenges such as food security and environmental sustainability. The company's dedication to these values and philosophy drives its mission to create a healthier and more sustainable future.

8 analysts currently rate the Calyxt stock: 0 recommend buying, 5 holding and 3 selling.

The Calyxt share (CLXT) is listed on 1 stock exchanges, including: NASDAQ (CLXT).

Calyxt Inc. is a plant breeding company specializing in the research, development, and marketing of innovative plant products. The company was founded in 2010 and is based in Minneapolis, Minnesota. Calyxt focuses on developing plant-based products that offer higher food quality, aiming for sustainable and environmentally friendly food production without the use of artificial chemicals or genetic engineering. They work closely with farmers, retailers, food manufacturers, and consumers. Calyxt has several business areas: 1. Plant gene editing technology: Calyxt has a unique plant gene editing technology that allows the company to influence plant growth, resistance to pests and diseases, and the content of certain nutrients. The company uses a precision method that improves plants without the use of genetic engineering, while still achieving a high degree of precision in gene modification. 2. Soybean and canola cultivation: Calyxt produces and sells high-quality soybean and canola products. These products are resistant to certain herbicides and have higher yields and better quality compared to conventional soybeans and canola. 3. Lentil variety: Calyxt has developed a special lentil variety that is considered a superfood due to its higher nutrient density. This lentil variety is rich in proteins, fiber, and minerals, and contains fewer carbohydrates than traditional lentils. 4. Grain products: Calyxt also offers grain products, specifically wheat and barley, which provide higher yield stability and optimal use of water and fertilizers. The company has launched several products, including a low-acrylamide potato, a high-oil seed, and a healthy lentil variety. Calyxt is also working on developing disease-resistant plants that are less susceptible to diseases and pests. Calyxt aims to promote sustainability in agriculture by developing products that allow farmers to grow more on less land while using less water and fertilizers. Calyxt Inc. presents an alternative to traditional breeding methods. By using safe plant gene editing technology, they can increase the nutritional value of food, reduce the use of pesticides and fertilizers, and lessen the environmental impact of agriculture. Through continuing this work and developing new technologies and products, Calyxt will play an important role in meeting the future demands of the agricultural industry.

The revenue cannot currently be calculated for Calyxt.

The profit cannot currently be calculated for Calyxt.

The P/E ratio cannot be calculated for Calyxt at the moment.

The P/S cannot be calculated for Calyxt currently.

The Eulerpool Quality Score for Calyxt is 2/10.

The ISIN of Calyxt is US13173L1070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Calyxt is A2DU9F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Calyxt is CLXT. The ticker symbol is used to trade Calyxt shares on the stock exchange.

Calyxt is assigned to the 'Health' sector.

The dividends of Calyxt are distributed in USD.

All fundamentals and in-depth analysis of Calyxt

Our stock analysis for Calyxt stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Calyxt. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.